Visanne receives PBS Listing in Australia, with subsidised treatment for endometriosis for over one million women and improved access to essential healthcare.

In a first in more than three decades, subsidised treatment for endometriosis will now be made available to over a million Australians suffering from this condition under the federal government. A necessary boon for women with the condition, Health Minister Mark Butler announced Sunday the daily dosing tablet Visanne (dienogest) will be covered by the Pharmaceutical Benefits Scheme (PBS).

Many women experience endometriosis, which causes tissue that looks like uterine lining to grow outside of the uterus, and include severe period pain, fatigue, and decreased fertility. Butler emphasized that women have always been brushed aside, barked out names like 'hysterical or drug-seeking.

Visanne works by shrinking and suppressing the growth of tissue that is abnormal, and this proves relief to a greater extent. Nikki Steendam, who has, for 46 years, lived with endometriosis, recounts how she received this drug's effects - "It has helped me take back my life. My day-to-day life is much better, the pain is gone, and I don't need pain medication."

The move to add Visanne on the PBS will indeed come under a more extensive investment in health by the federal government in the amount of $107 million to help Australians with endometriosis. This also includes research, treatment, and interventions. Out of pocket costs could be $750 a year without this subsidy for the patients.

Endometriosis can tear lives into for decades without a cure; therefore, pundits like Prof Jason Abbott of the University of NSW emphasize liberal affordability access in options of health care for warring endometriosis patients.